Societe De Conseils De Recherches Et D'applications Scientifiques Sas

Praecis Pharmaceuticals, Inc.

Glaxosmithkline LLC

Ipsen Pharma S.a.s.

Other

The Administrators of the Tulane Educational Fund

Societe De Conseils De Recherches Et D'applications Scientifiques (s.c.r.a.s.)

Biomeasure Incorporated

Soci&eacute;t&eacute; De Conseils De Recherches Et D'applications Scientifiques, S.a.s.

Barry A Morgan

Thomas D Gordon

Christopher C Arico-Muendel

Malcolm J Kavarana

Malcolm L Gefter

Richard W Wagner

Dennis R Benjamin

David I Israel

Matthew Clark

Stephen Paul Hale

Nils Jakob Vest Hansen

Raksha A Acharya

George J Franklin

Christophe Thurieau

Gary Olson

Christopher Self

Lydie Francine Poitout

Charles Michael Cook

Lily Lee

Jens Birktoft

Marie-Odile Galcera

Paolo A Centrella

David H Coy

William A Murphy

Christophe Philippe Moinet

Steffen Phillip Creaser

Dennis C H Bigg

Dean Sadat-Aalaee

Steffan Phillip Creaser

Nils Jakob Hansen

Michael DeWitt Culler

Ashis K Saha

Jacques Pommier

Christophe Moinet

Grégoire Prevost

Joseph P Marino, Jr

Ghotas Evindar

Yun Ding

Marie-Odile Lonchampt

Peng Li

Alexander L Satz

Koichi Yamashita

Terunori Mitsuma

Hiroshi Kaneko

Allyn T Londregan

Paulo A Centrella

Joseph Paul Marino

Mathew A Clark

Allyn T Longdregan

The invention features somatostatin antagonists having a D-amino acid at the second residue.

Somatostatin antagonists

The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.

Methods for synthesis of encoded libraries

The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

sEH inhibitors and their use

The present invention provides a method for identifying a compound of interest by screening libraries of molecules which include an encoding oligonucleotide tag.

Methods for identifying compounds of interest using encoded libraries

The present invention provides methods of synthesizing a molecule comprising a functional moiety which is operatively linked to an encoding oligonucleotide. The methods include providing an initiator compound comprising an initial functional moiety comprising n building blocks, wherein the initial functional moiety comprises at least one reactive group, and is operatively linked to an initial oligonucleotide; reacting the initiator compound with a building block comprising at least one complementary reactive group, under conditions suitable for reaction of the complementary reactive group to form a covalent bond; and reacting the initial oligonucleotide with an incoming oligonucleotide corresponding to the building block in the presence of an enzyme which catalyzes ligation of the initial oligonucleotide and the incoming oligonucleotide, under conditions suitable for ligation of the incoming oligonucleotide and the initial oligonucleotide to form an encoding oligonucleotide.

The present invention provides methods of synthesizing libraries of molecules comprising a functional moiety which is operatively linked to an encoding oligonucleotide, wherein the encoding oligonucleotide comprises a capping sequence containing degenerate nucleotides. The methods generally include providing a solution comprising initiator compounds comprising an initial functional moiety comprising n building blocks which is operatively linked to an initial oligonucleotide; dividing the solution into reaction vessels; reacting the initiator compounds in each reaction vessel with a building block comprising a complementary reactive group to form a covalent bond; and reacting the initial oligonucleotide in each aliquot with a distinct incoming oligonucleotide in the presence of an enzyme which catalyzes the ligation of the incoming oligonucleotide and the initial oligonucleotide, under conditions suitable for enzymatic ligation of the incoming oligonucleotide and the initial oligonucleotide to form an encoding oligonucleotide.

The present invention provides methods of synthesizing libraries of molecules comprising a functional moiety which is operatively linked to an encoding oligonucleotide. The methods generally include providing a solution comprising initiator compounds comprising an initial functional moiety which comprises n building blocks which comprise at least one reactive group, which is operatively linked to an initial oligonucleotide; dividing the solution into reaction vessels; reacting the initiator compounds in each reaction vessel with a building block comprising a complementary reactive group to form a covalent bond; and reacting the initial oligonucleotide in each aliquot with a distinct incoming oligonucleotide in the presence of an enzyme which catalyzes the ligation of the incoming oligonucleotide and the initial oligonucleotide, under conditions suitable for enzymatic ligation of the incoming oligonucleotide and the initial oligonucleotide to form an encoding oligonucleotide which identifies the structure of the functional moiety.

A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR)(CH)Z(CH)where Z is O, N(R), S, or a bond; Y is CO, CH, CS, or a bond; Ris or N(RR); and the remaining substituents are as defined in the disclosure.

Prenyl transferase inhibitors

The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonist or antagonists of somatostatin receptors.

Imidazolyl derivatives

The present invention is directed to imidazolyl derivatives of formula (I) where the substituents are defined in the specification, which are useful as agonists or antagonists of somatostatin receptors. 

A family of compounds capable of inhibiting the activity of farnesyl transferase.

Farnesyl transferase inhibitors

The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.

Therapeutic agents and methods of use thereof for the treatment of melanoma

Growing community of inventors

Waltham, MA, United States of America

Barry A Morgan